120281-58-5

Upstream product

• 106-41-2 4-bromo-phenol 
• 61570-79-4 1,1-dimethyl-2-propynyl trifluoroacetate 
• 115-19-5 2-methyl-but-3-yn-2-ol 
• 1972-28-7 diethylazodicarboxylate 
• 1111-97-3 3-chloro-3-methylbut-1-yne 

Downstream Products

• 185316-61-4 2,2-Dimethyl-6-phenylsulfanyl-2H-chromene 
• 185316-60-3 2,2-dimethyl-N-phenyl-2H-1-benzopyran-6-carboxamide 
• 126856-29-9 2,2-dimethyl-6-phenyl-sulfonyl-2H-chromene 
• 1386351-92-3 C₂₁H₂₄O₄ 
• 331947-87-6 2-(3,4-dimethoxyphenyl)-1-(2,2-dimethyl-2H-chromen-6-yl)ethanone 
• 264265-04-5 bis[4-(dimethylamino)phenyl](2,2-dimethyl-6-chromenyl)methanol 

Relevant academic research and scientific papers

NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT

The present invention relates to a novel compound inhibiting Hsp 90 and to a pharmaceutical composition including same as an active ingredient. Compounds of formula 1 and formula 2 according to the present invention inhibit the accumulation of HIF-1α protein, which is an Hsp90 client protein, by suppressing Hsp90 expression, and effectively inhibit the activity of vascular endothelial growth factor (VEGF). Furthermore, said compounds have low cytotoxicity and can thus be used as an active ingredient for the treatment of diabetic retinopathy and arthritis.

NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT

The present invention relates to a compound inhibiting Hsp90 and a pharmaceutical composition comprising the same as an active ingredient. The compounds represented by formula 1 and formula 2 of the present invention suppress the expression of Hsp90 so that they can inhibit the accumulation of HIF-1α, the Hsp90 client protein, and also efficiently inhibit the activation of VEGF. In addition, these compounds display low cytotoxicity, so that they can be effectively used as an active ingredient of an anti-cancer agent, a diabetic retinopathy treating agent, and an anti-arthritic agent.

Copper-catalyzed intramolecular carbotrifluoromethylation of alkynes for the construction of trifluoromethylated heterocycles

A mild and efficient copper-catalyzed intramolecular carbotrifluoromethylation of alkynes has been achieved in the presence of Togni reagent as trifluoromethylating reagent. The reaction tolerates a range of substrates to give a group of trifluoromethylated heterocycles with high selectivities. A plausible mechanism was proposed on the basis of experimental results. And the Togni award goes to Copper-catalyzed intramolecular carbotrifluoromethylation of alkynes is carried out with a Togni reagent as the trifluoromethylating reagent (see scheme). Various trifluoromethylated heterocycles are synthesized in moderate to good yields. Moreover, a range of common functional groups is tolerated under the reaction conditions.

Asymmetric epoxidation of alkenes catalyzed by a porphyrin-inspired manganese complex

A novel strategy for catalytic asymmetric epoxidation of a wide variety of olefins by a porphyrin-inspired chiral manganese complex using H 2O2 as a terminal oxidant in excellent yield with up to greater than 99% ee has been successfully developed.

A Convenient Synthesis of 6-Substituted-2,2-dimethyl-2H-1-benzopyrans

Various 2,2-dimethyl-6-functional-2H-1-benzopyrans were prepared via a halogen-metal exchange reaction followed by treatment with electrophiles. These 6-functionalized chromenes are important synthetic intermediates for preparation of benzopyran-based pot

Copper(I) iodide: A catalyst for the improved synthesis of aryl propargyl ethers

Copper(I) iodide catalyses the reaction between phenols and dialkylpropargyl chlorides to give aryl 1,1-dialkylpropargyl ethers 5 a-k and 7a-e in good yields and purity. These ethers are important as precursors to the 2H-1-benzopyrans 8a-l and 9a-e.

Benzopyran derivatives

Compounds of the formula STR1 wherein R 1 is hydrogen, halogen, trifluoromethyl, nitro, cyano, lower alkyl, lower alkoxycarbonyl, lower alkylthio, lower alkylsulphonyl, lower alkanoyl, aroyl, carbamoyl, mono(lower alkyl)carbamoyl or di(lower alkyl)carbamoyl, R 2 is hydrogen, lower alkyl or phenyl, R 3 is hydrogen or lower alkyl, R 4 and R 5 each is hydrogen or R 4 is hydroxy and R 5 is hydrogen or R 4 and R 5 together are a carbon-carbon bond and R 6 is an aryl or N-heteroaryl group carrying a hydroxy group in the 2-position or, in the case of a N-heteroaryl group, also a N-oxide group in the 2-position, and pharmaceutically acceptable acid addition salts of these compounds of formula I which are basic, possess pronounced potassium channel activating activity and can be used as medicaments, particularly in the control or prevention of hypertension, congestive heart failure, angina pectoris, peripheral and cerebral vascular disease and smooth muscle disorders.